Enhancing using glucose encapsulation, the efficacy of CdO NPs against multi-drug resistant Escherichia coli.

In this study, monodispersed, highly biocompatible and substantially stable glucose encapsulated CdO nanoparticles (G-CdO NPs) of uniform sizes were synthesized using a sol-gel route. In addition, naked CdO (n-CdO) NPs without any capping or surface functionalization were synthesized using the same method. These NPs were uniformly dispersed in an aqueous solution. The synthesis of G-CdO and n-CdO NP was confirmed by UV-Vis spectroscopy, transmission electron microscopy (TEM), zeta potential, and dynamic light scattering analyses. The average size of G-CdO and n-CdO NP was found to be 17±1and 27 ±â€¯1 nm, under TEM, respectively. X-ray diffraction analysis of G-CdO and n-CdO NPs confirmed their sizes to be 18.83 and 28.41 nm, respectively, and revealed their cubic crystal structures with no impurity. The surface functionalization of G-CdO NPs with glucose was confirmed by Nuclear Magnetic Resonance and Fourier-transform infrared spectroscopy analyses. As per our knowledge, this is the first report to investigate the potencies of G-CdO and n-CdO NPs against gram-negative and gram-positive multi-drug resistant (MDR) bacteria. The minimum inhibitory concentrations of G-CdO and n-CdO NPs were6.42 and 16.29 µg/ml, respectively, against Escherichia coli (NCIM 2571-MDR), whereas 7.5 µg/ml & 11.6 µg/ml, respectively against S. aureus (NCIM- 2079) as determined by the double dilution method. The minimum bactericidal concentration was determined at the concentration for which no growth was observed. TEM analysis of E. coli cells treated with G-CdO NPs revealed cell shrinkage and degraded cell membranes, while the cell surfaces of untreated viable cells were smooth.

Axillary Recurrence in Breast Cancer Patients After Negative Sentinel Lymph Node Biopsy: Retrospective Cohort Study From Riyadh, Saudi Arabia.

Breast cancer (BC) is among the most prevalent cancers globally. For minimally invasive axillary staging in early breast cancer, sentinel lymph node biopsy (SLNB) is commonly regarded as the gold standard. Historically, axillary lymph node dissection (ALND) was used as a staging procedure, but the less morbid SLNB has now replaced it. This retrospective cohort study, undertaken with patients at King Saud University Medical City in Riyadh, Saudi Arabia, evaluates mid-term follow-up data on axillary recurrences and outcomes for breast cancer patients with negative SLNB. The results indicate that the five-year risk of developing regional recurrence following negative SLNB is 0% in breast cancer patients. The low relapse rate further contributes to the evidence base suggesting the efficacy of SLNB and the higher morbidity associated with ALND. Future researchers should conduct a nationwide and long-term follow-up study to offer additional insights into the efficacy of SLNB.